Immunology & Inflammation

Shop By

33 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. CXCR2 ligand

    SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.
  2. IRAK modulator

    IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
  3. HPGDS inhibitor

    HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.
  4. 2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells.
  5. Nrf2 inhibitor

    Nrf2-IN-1 (Compound 4f) is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2), acts as a promising agent in acute myeloid leukemia (AML) therapy.
  6. iNOS Inhibitor

    GW274150 is a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury.
  7. L-PGDS inhibitor

    AT-56 is am orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 μM, IC50 = 95 μM).
  8. COX-1 and COX-2 inhibitor

    Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
  9. PD-1/PD-L1 interaction inhibitor

    BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
  10. Megakaryocytes/platelets inducing agent is an inducing agent for megakaryocytes and/or platelets from pluripotent stem cells, the inducing agent being useful in treating diseases involving thrombopenia.
  11. COX-2 Inhibitor

    FK3311 is a cell-permeable and orally available sulfonanilide that acts as a selective COX-2 inhibitor and NSAID.
  12. CCR2/CCR5 inhibitor

    Cenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
  13. TLR7 agonist

    Isatoribine is a novel guanosine analogue showing immunostimulatory activity both in vivo and in vitro.
  14. CXCR2/CXCR1 antagonist

    SCH 563705 is a potent dual CXCR2(IC50= 1.3 nM)/CXCR1(IC50= 7.3 nM) antagonist.
  15. Arginase Inhibitor

    CB-1158, also known as INCB01158, is a potent and orally active arginase inhibitor with IC50=89 nM) .
  16. IL-1 receptor antagonist

    AF 12198 is a potent and selective antagonist for the human type I interleukin-1 (IL-1) receptor.
  17. TLR4 antagonist

    IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein.
  18. CXCR4 receptor antagonist

    USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.
  19. PGS inhibitor

    PGS-IN-1 is a potent inhibitor of prostaglandin synthetase (PGS) with an IC50 of 0.28 μM; also inhibits 5-lipoxygenase with an IC50 of 1.05 μM.
  20. IL receptor agonist

    NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone. NO-prednisolone potently stimulates IL-10 production in vivo.
  21. Human CXCR3 agonist

    PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity, which inhibits the binding of CXCR3 ligand CXCL10 to CXCR3 receptor with IC50 of 42 nM.
  22. Arglabin is a sesquiterpene gamma-lactone is isolated from Artemisia glabella; anticancer natural compound.
  23. arginases I and II inhibitor

    Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.
  24. human CX3CR1 receptor modulator

    AZD8797 is an allosteric non-competitive and orally active modulator of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.
  25. CCR9 antagonist

    Vercirnon (GSK-1605786) is an orally bioavailable, selective, and potent antagonist of CCR9, with an IC50 of 10 nM, used in the research of inflammatory bowel diseases.
  26. PD-1/PD-L1 interaction inhibitor

    BMS-1166 hydrochloride is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
  27. cGAMP (Cyclic GMP-AMP; 3',3'-cGAMP) is an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA; STING ligand.
  28. Nrf2 inhibitor

    AEM1 is an inhibitor of deregulated NRF2 transcriptional activity in cancer.
  29. CCR8 inhibitor

    R243 is an inhibitor of CCR8 signaling and chemotaxis.
  30. ROS1/NTRK inhibitor

    Taletrectinib (DS-6051b) is a potent, orally active, and new-generation selective ROS1/NTRK inhibitor.
  31. Norbergenin, also known as Demethylbergenin, is the O-demethyl derivative of bergenin, the main component of Mallotus japonicus.It shows moderate antioxidant activity with IC(50)= 13 μM in DPPH radical scavenging and 32 μM in superoxide anion scavenging.
  32. COX inhibitor

    Pamicogrel (KBT3022) is a cyclooxygenase (COX) inhibitor.
  33. PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.

33 Items

per page
Set Descending Direction